Description: Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Home Page: www.regeneron.com
777 Old Saw Mill River Road
Tarrytown,
NY
10591-6707
United States
Phone:
914 847 7000
Officers
| Name | Title |
|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman |
| Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research |
| Mr. Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply |
| Mr. Christopher R. Fenimore CPA | Senior VP of Finance & CFO |
| Ms. Patrice Gilooly | Senior Vice President of Quality Assurance & Operations |
| Mr. Bob McCowan | Senior VP of IT & Chief Information Officer |
| Mr. Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis |
| Mr. Joseph J. LaRosa J.D. | Executive VP, General Counsel & Secretary |
| Ms. Melissa Lozner | Senior VP & Chief Compliance Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 17.331 |
|---|---|
| Trailing PE: | 19.34 |
| Price-to-Book MRQ: | 2.9289 |
| Price-to-Sales TTM: | 5.7971 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 14165 |